OnKure Therapeutics (NASDAQ:OKUR) Rating Lowered to Hold at JonesTrading

OnKure Therapeutics (NASDAQ:OKUR) was downgraded by analysts at JonesTrading from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on OKUR. Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings upgraded OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Finally, HC Wainwright lowered their price objective on OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, March 16th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $27.00.

OnKure Therapeutics Price Performance

OKUR opened at $3.91 on Thursday. The stock’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $3.32. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $5.38. The firm has a market cap of $53.45 million, a price-to-earnings ratio of -0.90 and a beta of 0.36.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.37). As a group, sell-side analysts anticipate that OnKure Therapeutics will post -2.84 EPS for the current year.

Institutional Trading of OnKure Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC bought a new stake in OnKure Therapeutics during the fourth quarter valued at about $58,000. XTX Topco Ltd bought a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $52,000. ADAR1 Capital Management LLC bought a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $2,941,000. Kotler Kevin bought a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $573,000. Finally, Barclays PLC raised its holdings in shares of OnKure Therapeutics by 4,286.8% in the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after buying an additional 26,621 shares during the period. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.